-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCT-1000 in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCT-1000 in Vulvar Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCT-1000 in Vulvar Cancer Drug Details: SCT-1000 is under development for the...
-
Product Insights
Vulvar Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvar Cancer - Drugs In Development, 2023’, provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vaginal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vaginal Cancer - Drugs In Development, 2023’, provides an overview of the Vaginal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Penile Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Penile Cancer - Drugs In Development, 2023’, provides an overview of the Penile Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Penile Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Anal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Cancer - Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Oropharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Oropharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Oropharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bis-5 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Small-Cell Lung Cancer Drug Details: Bis5 (LB-1410) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGN-STNV in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SGN-STNV in Pancreatic Cancer Drug Details: SGN-STNV is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ECI-001 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ECI-001 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ECI-001 in Breast Cancer Drug Details: ECI-001 is under development for the...